Advertisement
Advertisement
NVCR
NovoCure Limited Ordinary Shares
14.94
USDSponsored
-0.98
-6.16%
Oct 02, 16:00 UTC -4
Closed
After-Market
15.07
+0.13
+0.90%
NVCR Earnings Reports
Positive Surprise Ratio
NVCR beat 25 of 43 last estimates.
58%
Next Report
Date of Next Report
Oct 26, 2026
Estimate for Q3 26 (Revenue/ EPS)
$185.88M
/-$0.24
Implied change from Q2 26 (Revenue/ EPS)
+1.25%
/+41.18%
Implied change from Q3 25 (Revenue/ EPS)
+11.17%
/-27.27%
NovoCure Limited Ordinary Shares earnings per share and revenue
On Jul 23, 2026, NVCR reported earnings of -0.17 USD per share (EPS) for Q2 26, beating the estimate of -0.33 USD, resulting in a 49.72% surprise. Revenue reached 183.58 million, compared to an expected 175.89 million, with a 4.38% difference. The market reacted with a +28.39% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 7 analysts forecast an EPS of -0.24 USD, with revenue projected to reach 185.88 million USD, implying an increase of 41.18% EPS, and increase of 1.25% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nanobiotix S.A. - ADR
Report Date
Sep 25, 2026 For Q2 26
Estimate
-$0.11
Actual
-$0.70
Surprise
-496.76%
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$0.07
Surprise
+2,158.06%
Inventiva S.A. - ADR
Report Date
Sep 28, 2026 For Q2 26
Estimate
-$0.37
Actual
-$0.25
Surprise
+33.55%
Rezolute, Inc. Common Stock (NV)
Report Date
Sep 24, 2026 For Q4 26
Estimate
-$0.15
Actual
-$0.20
Surprise
-32.45%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
$0.00
Surprise
+99.70%
Palatin Technologies, Inc. Common Stock
Report Date
Sep 28, 2026 For Q4 26
Estimate
-$1.21
Actual
-$1.11
Surprise
+8.42%
NeuroSense Therapeutics Ltd. Ordinary Shares
Report Date
Sep 25, 2026 For Q2 26
Estimate
-$3.26
Actual
-$2.10
Surprise
+35.66%
FAQ
What were NovoCure Limited Ordinary Shares's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, NovoCure Limited Ordinary Shares reported EPS of -$0.17, beating estimates by 49.72%, and revenue of $183.58M, 4.38% above expectations.
How did the market react to NovoCure Limited Ordinary Shares's Q2 2026 earnings?
The stock price moved up 28.39%, changed from $15.57 before the earnings release to $19.99 the day after.
When is NovoCure Limited Ordinary Shares expected to report next?
The next earning report is scheduled for Oct 26, 2026.
What are the forecasts for NovoCure Limited Ordinary Shares's next earnings report?
Based on 7
analysts, NovoCure Limited Ordinary Shares is expected to report EPS of -$0.24 and revenue of $185.88M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.